CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • IDYA Dashboard
  • Financials
  • Filings
  • Transcripts
  • ETFs
  • Insider
  • Institutional
  • Shorts
  • News
  • Patents
  • Reddit

Ideaya Biosciences (IDYA)

Company Profile
IDEAYA Biosciences Inc. is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality - which represents an emerging class of precision medicine targets.
Ideaya Biosciences logo

Company profile

Ticker
IDYA
Exchange
NASDAQ
Website
www.ideayabio.com
CEO
Yujiro Hata
Employees
Incorporated
Delaware
Location
California
Fiscal year end
Dec 31
Sector
Professional, Scientific, and Technical Services > Research and Development in Biotechnology
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...
SEC CIK
0001676725
Corporate docs
Articles of Incorporation & Bylaws
Underwriting Agreements
Indentures
Material Contracts & Credit Agreements
IRS number
474268251

IDYA stock data

Analyst ratings and price targets

Last 3 months
Current price
Average target
$26.50
Low target
$24.00
High target
$29.00
Capital One
Initiated
Overweight
$29.00
28 Dec 22
Baird
Maintains
Outperform
$24.00
18 Nov 22
Latest filings (excl ownership)
View all
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
IDEAYA Biosciences, Inc. Reports Third Quarter 2022
8 Nov 22
8-K
Other Events
19 Sep 22
424B5
Prospectus supplement for primary offering
15 Sep 22
424B5
Prospectus supplement for primary offering
14 Sep 22
8-K
Other Events
14 Sep 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
8-K
IDEAYA Biosciences, Inc. Reports Second Quarter 2022
15 Aug 22
8-K
IDEAYA Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors
27 Jul 22
8-K
Submission of Matters to a Vote of Security Holders
10 Jun 22
Transcripts
IDYA
Earnings call transcript
2021 Q4
15 Mar 22
Latest ownership filings
View all
SC 13G/A
FEDERATED HERMES, INC.
1 Feb 23
SC 13G/A
BlackRock Inc.
31 Jan 23
3
Darrin Beaupre
14 Dec 22
SC 13G
ADAGE CAPITAL PARTNERS GP, L.L.C.
27 Oct 22
4
WENDY L YARNO
10 Jun 22
4
TIMOTHY M SHANNON
10 Jun 22
4
TERRY J ROSEN
10 Jun 22
4
Susan L. Kelley
10 Jun 22
4
Susan L. Kelley
10 Jun 22
4
Scott W Morrison
10 Jun 22

Financial summary

Financial statements Chart IDYA financial data
Quarter (USD) Sep 22 Jun 22 Mar 22 Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 102.06 mm 102.06 mm 102.06 mm 102.06 mm 102.06 mm 102.06 mm
Cash burn (monthly) (no burn) 539.50 k (no burn) 4.54 mm 8.06 mm 6.71 mm
Cash used (since last report) n/a 2.27 mm n/a 19.07 mm 33.86 mm 28.18 mm
Cash remaining n/a 99.79 mm n/a 82.99 mm 68.20 mm 73.88 mm
Runway (months of cash) n/a 185.0 n/a 18.3 8.5 11.0

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

IDYA institutional ownership history Ownership history
13F holders Current Prev Q Change
Total holders 115 99 +16.2%
Opened positions 28 10 +180.0%
Closed positions 12 17 -29.4%
Increased positions 46 30 +53.3%
Reduced positions 22 37 -40.5%
13F shares Current Prev Q Change
Total value 709.23 mm 915.45 mm -22.5%
Total shares 49.01 mm 40.88 mm +19.9%
Total puts 0.00 0.00
Total calls 308.90 k 330.50 k -6.5%
Total put/call ratio – – –
Largest owners Shares Value Change
Logos Global Management 4.14 mm $61.69 mm +10.3%
Avidity Partners Management 3.72 mm $55.43 mm +25.0%
BVF 3.29 mm $49.16 mm +17.9%
FHI Federated Hermes 2.86 mm $42.70 mm +32.4%
BLK Blackrock 2.68 mm $39.92 mm +2.0%
Canaan Partners X 2.66 mm $39.70 mm 0.0%
Boxer Capital 2.20 mm $32.87 mm 0.0%
Biotechnology Value Fund L P 1.96 mm $21.00 mm 0.0%
Vanguard 1.92 mm $28.72 mm +9.8%
T. Rowe Price 1.86 mm $27.74 mm -1.5%
Largest transactions Shares Bought/sold Change
Adage Capital Partners GP, L.L.C. 1.85 mm +1.75 mm +1672.1%
Deerfield Management 1.74 mm +1.74 mm NEW
Baker Bros. Advisors 1.67 mm +1.67 mm NEW
Point72 Asset Management 0.00 -1.51 mm EXIT
STT State Street 0.00 -1.48 mm EXIT
Avidity Partners Management 3.72 mm +742.45 k +25.0%
FHI Federated Hermes 2.86 mm +700.00 k +32.4%
Sofinnova Investments 654.76 k +654.76 k NEW
Citadel Advisors 1.25 mm +533.64 k +74.0%
BVF 3.29 mm +500.00 k +17.9%
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

IDYA insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
9 Jun 22 Hampton Malcolm Garret Stock Option Common Stock Grant Acquire A No No 12.29 11,000 135.19 k 11,000
9 Jun 22 Stein Jeffrey Stock Option Common Stock Grant Acquire A No No 12.29 11,000 135.19 k 11,000
9 Jun 22 Morrison Scott W Stock Option Common Stock Grant Acquire A No No 12.29 11,000 135.19 k 11,000
9 Jun 22 Kelley Susan L. Stock Option Common Stock Grant Acquire A No No 12.29 11,000 135.19 k 11,000
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro
IDEYA Initiated Phase 2 Clinical Trial Evaluating Darovasertib As Neoadjuvant Treatment Of Uveal Melanoma Prior To Primary Interventional Treatment Of Enucleation Or Radiation Therapy
23 Jan 23
IDEAYA Biosciences, Inc.
IDEAYA Announces IND Clearance By U.S. FDA Enabling Phase 1 Initiation For First-in-Class PARG Development Candidate IDE161
9 Jan 23
- Targeting to initiate dosing of Phase 1 clinical trial in Q1 2023 to evaluate IDE161 in patients having tumors with HRD, including BRCA1/2-mutant breast and ovarian cancer - Starting dose of IDE161 in the
Benzinga's Top Ratings Upgrades, Downgrades For December 28, 2022
28 Dec 22
Capital One Initiates Coverage On IDEAYA Biosciences with Overweight Rating, Announces Price Target of $29
28 Dec 22
IDEAYA Biosciences Announces Submission Of IND Application To The U.S. FDA For PARG Development Candidate IDE161
12 Dec 22

Press releases

From Benzinga Pro
IDEAYA Biosciences to Participate in the 2023 Guggenheim Oncology Conference
1 Feb 23
SOUTH SAN FRANCISCO, Calif., Feb. 1, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted
IDEAYA Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma
23 Jan 23
- Initiated Phase 2 clinical trial evaluating Darovasertib as neoadjuvant treatment of uveal melanoma prior to primary interventional treatment of enucleation or radiation therapy - Clinical protocol includes
IDEAYA Announces IND Clearance by U.S. FDA enabling Phase 1 Initiation for First-in-Class PARG Development Candidate IDE161
9 Jan 23
- Targeting to initiate dosing of Phase 1 clinical trial in Q1 2023 to evaluate IDE161 in patients having tumors with HRD, including BRCA1/2-mutant breast and ovarian cancer - Starting dose of IDE161 in the Phase 1 dose
IDEAYA Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
3 Jan 23
IDEAYA Biosciences Appoints Dr. Karlene Cimprich, Ph.D. and Dr. Kornelia Polyak, M.D., Ph.D. to Scientific Advisory Board
19 Dec 22
Finsight
Resources
  • Knowledgebase
  • Log In
  • Register
Company
  • About
  • Contact
  • Solutions
Products
  • Deal Roadshow
  • DealVDR
  • Evercall
  • Finsight.com
CapEdge
  • Earnings Calendar
  • Earnings Transcripts
  • EDGAR Filing Screener
  • IPO Calendar
  • Compliance
  • Privacy
  • Security
  • Terms
AngelList LinkedIn